The research funded by AB-Biotics explored a three-strain probiotic blend, consisting of Lactobacillus brevis KABP052, Lactobacillus plantarum KABP051, and Pediococcus acidilactici KABP021, focusing on its effects on menopause-related symptoms and quality of life. This blend is marketed as KABP Menopause in the US and Gyntima Menopause in Europe.
Key Findings:
- Women using the probiotic blend reported significant improvements in symptoms such as hot flashes, sleep disturbances, and mood-related issues compared to those taking a placebo.
- More than one billion women globally experience menopausal symptoms, which can last from 7 to 15 years, highlighting a significant gap in effective treatments.
- Gut microbiota changes during menopause may influence symptoms, with probiotics emerging as a potential non-hormonal support option.
Study Design:
- The study was a three-month, randomized, double-blind, placebo-controlled trial involving women aged 45–60 who are perimenopausal or postmenopausal.
- Participants took either a daily probiotic capsule or a placebo containing only maltodextrin.
- Evaluations included the Menopause Rating Scale II and Cervantes Quality of Life Scale.
Results:
- The probiotic group showed reduced menopausal symptoms and improved quality of life after three months.
- The blend may assist in estrogen reabsorption and support gut-brain health through the production of beneficial compounds.
- No significant effects were found regarding vaginal symptoms or overall quality-of-life scores.
Conclusion:
The findings suggest that KABP Menopause/Gyntima Menopause may effectively support women during menopause by addressing underlying symptom causes, especially with increasing demand for natural, hormone-free solutions.
